PHAT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHAT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Phathom Pharmaceuticals's Shareholder Yield % was -31.61%.
The historical data trend for Phathom Pharmaceuticals's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phathom Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Shareholder Yield % | Get a 7-Day Free Trial | - | 3.94 | -3.64 | -5.36 | -2.71 |
Phathom Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Shareholder Yield % | Get a 7-Day Free Trial | -5.36 | -23.08 | -70.41 | -0.89 | -2.71 |
For the Biotechnology subindustry, Phathom Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Phathom Pharmaceuticals's Shareholder Yield % falls into.
Phathom Pharmaceuticals's Shareholder Yield % for the quarter that ended in Dec. 2023 is calculated as:
Shareholder Yield % | = | Dividend Yield % | + | Buyback Yield % | + | Net Debt Paydown Yield % |
= | 0 % | + | 0 % | + | -2.71 % | |
= | -2.71 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Phathom Pharmaceuticals (NAS:PHAT) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Molly Henderson | officer: CFO and CBO | 305 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Asit Parikh | director | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Azmi Nabulsi | officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Frank Karbe | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
David A Socks | director, officer: President, CEO, Treas. & Sec. | C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Anthony J. Guzzo | officer: VP, Chief Accounting Officer | C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Todd P. Branning | officer: Chief Financial Officer | C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Mark Stenhouse | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Michael F Cola | director | 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945 |
Frazier Life Sciences Ix, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Jonathan S. Edwards | director | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Rajeev M. Shah | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By PRNewswire PRNewswire • 06-08-2023
By PRNewswire PRNewswire • 05-26-2023
By Marketwired • 08-10-2023
By PRNewswire PRNewswire • 05-31-2023
By PRNewswire • 08-25-2023
By Marketwired • 09-21-2023
By Marketwired • 09-26-2023
By sperokesalga sperokesalga • 06-12-2023
By sperokesalga sperokesalga • 05-30-2023
By PRNewswire PRNewswire • 06-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.